MediGene AG · LS:A40ESG
MediGene — Q1 2013 Earnings Presentation
13 slides from MediGene's earnings presentation, May 14, 2013
Slide 1: Analyst conference call: Results for the first 3 months of 2013
Analyst conference call Results for the first 3 months of 2013 14 May 2013 Peter Llewellyn-Davies, CFO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "will", "may" or words of simila
Slide 3: Major events since the beginning of 2013
Major events since the beginning of 2013 Veregen®: Inclusion of Veregen® in European treatment guidelines Market launch in Serbia Market approval in the Czech Republic Partnership agreements for marketing Veregen® in Asian countries, Australia and New Zealand EndoTAG®-1: Investigator Initiated Trial
Slide 4: Financial Report 3M 2013
medigene Financial Report 3M 2013
Slide 5: Financial highlights for 3M 2013
Financial highlights for 3M 2013 Revenue from royalties on Veregen® increased by 48% Increase of in-market sales by 47% up to € 3.5 m Demand on market steadily grows Without 2012 one-time effect: Total revenue increased by 6% to €1.3 m Loss on EBITDA basis reduced by 6% to €-2.3 m Total operating ex
Slide 6: Growing Veregen sales
Growing Veregen® sales In € m In € k In € k 13% 47% 6% Revenue (in € k) Q1 2012 Q1 2013 Change Veregen® Royalties 377 558 48% Revenue from supply chain 225 70 -69% Milestones 2 52 >200% Total Veregen® revenue 604 680 13% Other operating income 1,018 629 -38% One-time compensation payment 0 390 - Tot
Slide 7: Veregen: Status of global regulatory and marketing progress
Veregen®: Status of global regulatory and marketing progress Approval Preparation and Approval process Price negotiations On the market filing of dossier China* South Mexico Israel USA (2009) Korea France Germany (2010) Canada Romania Nordic countries Turkey Taiwan CEE countries Austria (2010) EU**
Slide 8: Total operating expenses remained stable
Total operating expenses remained stable In € k R&D expenses -5% 3% 1,840 1,753 Q1 2012 Q1 2013 Reduction in clinical trial expenses Higher costs for preclinical development Increase in SG&A expenses due to higher marketing costs for Veregen® Average monthly operating cash usage of €-1.1 m due to in
Slide 9: Improvement on EBITDA (excluding one-time effects)
Improvement on EBITDA (excluding one-time effects) In € k Reduction of EBITDA loss of 6% year-on-year (without one-time effect €0.4 m compensation payment) Difference between Q1 2012 and 2013 net result comprises Income from compensation payment (€0.4 m) and revaluation of investment (€2.2 m) in 201
Slide 10: Financial guidance for 2013 confirmed
Financial guidance for 2013 confirmed Guidance 2013 Actual 2012 Total revenue €7 - 8 m €6.3 m Veregen® €4.5 - 5.5 m €3.4 m Non-cash income €2.5 m €1.9 m EBITDA loss €9 - 11 m €9.4 m* *from continued operations Cash reach at least until end of 2014 Expected commercial expansion of Veregen® may si
Slide 11: Product and project outlook
Product and project outlook Veregen® Revenue growth in significant double-digit percent range Approvals and market launches in additional countries Additional marketing and partnership agreements EndoTAG®-1 Final data of phase II (IIT) to be published for ASCO 2013 Discussions with potential partner
Slide 12: Questions & Answers
medigene Questions & Answers
Slide 13: Medigene AG contact details
Medigene AG MediGene AG T +49 - 89 - 20 00 33 - 0 Lochhamer Straße 11 F +49 - 89 - 20 00 33 - 2920 82152 Planegg Planegg/Martinsried / Martinsried investor@medigene.com Germany www.medigene.com Listed on Frankfurt Stock Exchange (MDG, Prime Standard)